Blood cancer, Cancer, Leukemia, Relapsed/refractory acute myeloid leukemia
SNDXSyndax PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Revumenib (SNDX-5613) + venetoclax + decitabine and cedazuridine in Blood cancer, Cancer, Leukemia, Relapsed/refractory acute myeloid leukemia. The expected timing is based on the latest available company guidance and may change.
SAVE trial: 8/22/23- Investigator initiated trial (MD Anderson Cancer Center). 8/1/24- Trial expanding to validate RP2D with additional data at ASH '24. 12/7/24- Presented encouraging data at ASH. Plans to expand in newly diagnosed AML patients who are older or unfit for intensive chemo. 11/03/25:- SAVE Ph1/2 all-oral revumenib+venetoclax+decitabine/cedazuridine trial oral ASH 2025 presentation from first newly diagnosed cohort. 12/08/25:- ASH 2025 Ph2 SAVE newly diagnosed NPM1m/KMT2Ar AML cohort: 86% ORR, 76% CR, 100% MRD negativity. 02/26/26:- ASH 2025 SAVE Ph1/2 newly diagnosed cohort high CR, ORR, MRD-negativity reiterated; trial ongoing. 04/30/26:- SAVE Ph1/2 R/R AML NPM1m/KMT2Ar/NUP98r data expected from revumenib+venetoclax+decitabine/cedazuridine trial in Q2 2026. 05/12/26:- Updated SAVE trial R/R AML data will be presented at EHA 2026 June 12. 06/11/26:- SAVE Ph1/2 R/R AML reported 88% ORR and 68% MRD negativity among responders. 08/04/26:- SAVE Ph1/2 JCO data published; frontline data expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.